What topics does this cannabis study cover?

This study covers research on: THC, CBD, Inflammation.

Where was this research published?

Published in Scientific reports on July 16, 2026.

THC CBD Inflammation

High-THC cannabis briefly shifts inflammation, not insulin response

Q: What did this research study find?

Higher peak blood levels of *THC* were linked to **greater acute increases in inflammation** after cannabis use.

Inhaling high THC cannabis acutely increases inflammation but not insulin sensitivity: a quasi-randomized trial.

Scientific reports • July 16, 2026 • Highly Relevant

🤖

AI Summary

This quasi-randomized trial examined the short-term effects of inhaling THC-dominant, CBD-dominant, or combined CBD + THC cannabis flower. The study included 108 adults who smoked a pre-rolled cannabis cigarette as much as they wished, with researchers measuring blood markers of inflammation and insulin sensitivity before and after use.

Higher peak blood levels of THC were associated with larger increases in inflammation after cannabis use. Cannabis also changed levels of both pro-inflammatory and anti-inflammatory cytokines, while the inflammatory marker MCP-1 decreased acutely. However, cannabis use did not change the Matsuda index, a measure of insulin sensitivity. For users, the findings suggest that a single session of high-THC cannabis can temporarily alter immune signaling, but this study does not show an immediate improvement or worsening of insulin sensitivity. Longer-term research is needed before drawing conclusions about diabetes or metabolic health.

💡 Key Findings

Higher peak blood levels of THC were linked to greater acute increases in inflammation after cannabis use.

Good

75%

Acute cannabis use affected both pro-inflammatory and anti-inflammatory cytokines, including an increase in IL-10 under some THC and CBD exposure conditions.

Good

70%

Cannabis use did not change insulin sensitivity as measured by the Matsuda index.

High

80%

The inflammatory marker MCP-1 decreased acutely after cannabis use.

Good

70%

📄 Original Abstract

Cannabis is linked with increased appetite, raising concern about obesity-related disease and type 2 diabetes. Yet data suggest metabolic benefits of cannabis through inflammatory processes and insulin sensitivity. This was a quasi-randomly assigned experimental study comparing acute effects of a CBD-dominant versus THC-dominant versus CBD + THC cannabis flower product. Data were collected from community participants through a mobile pharmacology laboratory and a clinical research center. Participants smoked their assigned pre-rolled cannabis flower cigarette ad libitum. Primary outcomes were IL-10, chemokine MCP-1, a composite of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-12, IFNG, and IL-4), and insulin sensitivity (Matsuda index). Outcomes were predicted by peak blood levels of THC and CBD immediately after cannabis use. Hypotheses were that inflammation and insulin sensitivity would vary as a function of CBD and THC exposure, and that inflammatory changes would be associated with insulin sensitivity. Participants (n = 108) were 25 to 45 (Mage = 29.7, sd = 5.4), 56.5% Female, and 88.0% white. Mixed effect models indicated a time X peak THC blood level interaction (B = 0.003, SE = 0.001, p = 0.037). As THC blood levels increased, inflammation increased more after acute use. There was a THC X CBD X time interaction on IL-10 (B=-0.001, SE = 0.000, p < 0.001). Higher than average peak blood THC was related to increasing IL-10 over time while lower than average peak THC was related to decreasing IL-10 over time but only at average or lower peak CBD levels. Cannabis use decreased MCP-1 acutely (effect for time: B=-48.757, SE = 15.061, p = 0.002), while there was no effect on the Matsuda Index. Acute cannabis use is associated with increases in both pro- and anti-inflammatory circulating cytokines, but not with insulin sensitivity. Additional research on the possible mediating mechanisms involved in the connection between cannabis use and type 2 diabetes is required.Trial registration: Gov NCT04114903, https://clinicaltrials.gov/study/NCT04114903, Registration date 11/08/2019.

Paper Type

📄 Research

Publication

Journal: Scientific reports
Published: July 16, 2026
PMID: 42463843
DOI: 10.1038/s41598-026-62837-0

Authors (7)

Angela D Bryan Department of Psychology and Neuroscience, University of Colorado Boulder, UCB 345, Boulder, 80309, CO, USA. angela.bryan@colorado.edu.
Carillon J Skrzynski Department of Psychology and Neuroscience, University of Colorado Boulder, UCB 345, Boulder, 80309, CO, USA.
Jinqiu Yang Department of Psychology and Neuroscience, University of Colorado Boulder, UCB 345, Boulder, 80309, CO, USA.
Kyle A Chrystal Department of Psychology and Neuroscience, University of Colorado Boulder, UCB 345, Boulder, 80309, CO, USA.
L Cinnamon Bidwell Department of Psychology and Neuroscience, University of Colorado Boulder, UCB 345, Boulder, 80309, CO, USA.
+2 more authors